Opioid use disorder is characterised by the persistent use of opioids despite the adverse
consequences of its use. The disorder is associated with a range of mental and general …

The opioid crisis has grown to affect pregnant women and infants across the United States,
as evidenced by rising rates of opioid use disorder among pregnant women and neonatal …

Background Although clinicians have traditionally used the Finnegan Neonatal Abstinence
Scoring Tool to assess the severity of neonatal opioid withdrawal, a newer function-based …

The prevention, assessment, and treatment of neonatal pain and agitation continues to
challenge clinicians and researchers. Substantial progress has been made in the past three …

Opioid use disorder continues to be a significant source of morbidity and mortality in the
USA and the world. Pharmacologic treatment with methadone and buprenorphine has been …

Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants
develop after intrauterine maternal drug exposure. All infants with documented in utero …

Objectives: Identify the etiology and epidemiology of neonatal abstinence syndrome.
Describe the typical presentation, evaluation options, and assessment tools for neonatal …

Importance Incidence of neonatal abstinence syndrome is rising rapidly, and optimal
pharmacotherapy may meaningfully reduce length of treatment. Objective To compare …

A significant number of advances have been made in the last 5 years with respect to the
identification, diagnosis, assessment, and management of infants with prenatal opioid …

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …